Per Holse Mygind

This inventor holds 15 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Antimicrobial Peptides. Top assignees: Novozymes Adenium Biotech A/s, Novozymes A/s, Defensin Therapeutics Aps. Active years: 2006-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Per Holse Mygind. Retrieved from https://idiyas.com/inventor/per-holse-mygind

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 13.3

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 53(Granted Patents)

Location History:

Soborg, DK (2011)
Soeborg, DK (2006 - 2012)
Vaerloese, DK (2012 - 2016)

Company Filing History:

6 out of 8

Novozymes Adenium Biotech A/s

Defensin Therapeutics Aps

Novozymes Adenivro Biotech A/s

patent

6. 1 out of 1

Novozymes Aderium Biotech A/s

patent

7. 1 out of 1

Novozymes Pharma Biotec A/s

patent

Years Active: 2006-2016

Loading Chart...

Areas of Expertise:

Inflammatory Bowel Diseases

Beta Defensins

Antimicrobial Activity

Polypeptides

Rheumatoid Arthritis

Peptide Variants

Recombinant Production

Polynucleotides

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9279010 - Treatment of inflammatory bowel diseases with mammal beta defensins (2016-03-08),

2. 8835604 - Antimicrobial peptide variants and polynucleotides encoding same (2014-09-16),

3. 8802621 - Treatment of inflammatory bowel diseases with mammal beta defensins (2014-08-12),

4. 8232248 - Treatment of rheumatoid arthritis with mammal beta defensins (2012-07-31),

5. 8232242 - Treatment of inflammatory bowel diseases with mammal beta defensins (2012-07-31),

6. 8192925 - Polypeptides having antimicrobial activity and polynucleotides encoding same (2012-06-05),

7. 8080390 - Antimicrobial polypeptides (2011-12-20),

8. 7972814 - [object Object] (2011-07-05),

9. 7935501 - Recombinant production of antimicrobial peptides (2011-05-03),

10. 7893196 - Polypeptides having antimicrobial activity and polynucleotides encoding same (2011-02-22),

11. 7829524 - Antimicrobial peptides (2010-11-09),

12. 7671175 - Polypeptides having antimicrobial activity and polynucleotides encoding same (2010-03-02),

13. 7504375 - Antimicrobial polypeptides (2009-03-17),

14. 7388077 - Polypeptides having antimicrobial activity and polynucleotides encoding the same (2008-06-17),

15. 7148404 - Antimicrobial polypeptides (2006-12-12),

Title: The Innovative Contributions of Per Holse Mygind

Introduction

Per Holse Mygind is a notable inventor based in Soeborg, Denmark. He has made significant contributions to the field of biomedical research, particularly in the treatment of inflammatory bowel diseases. With a total of 15 patents to his name, Mygind's work has had a profound impact on medical science.

Latest Patents

Among his latest patents, one focuses on the treatment of inflammatory bowel diseases using mammal beta defensins. This invention presents a novel approach to managing these conditions. Another significant patent involves antimicrobial peptide variants and the polynucleotides encoding them. This invention encompasses variants of a parent antimicrobial peptide, along with nucleic acid constructs, vectors, and host cells that utilize these polynucleotides.

Career Highlights

Throughout his career, Mygind has worked with prominent companies such as Novozymes and Adenium Biotech A/S. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in biotechnology.

Collaborations

Mygind has collaborated with several talented individuals in his field, including Dorotea Raventos Segura and Thomas Kruse. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Per Holse Mygind's contributions to the field of biomedical research are noteworthy. His innovative patents and collaborations highlight his commitment to advancing medical science. His work continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.